GRAIL’s mission is to detect cancer early, when it can be cured

Why early matters

Survival rates are higher when cancer is diagnosed at earlier stages.

However, effective screening only exists for a few cancer types, and most cancer is detected at later stages, when survival rates are much lower.

Late-Stage
Survival Rate

 

 

 

 

 

 

 

 

 

 

1X

Early-Stage
Survival Rate

 

 

 

 

 

 

 

 

 

 

5 - 10X higher

Aravanis AM, Lee M, Klausner RD. Cell. 2017; 168(4):571–574, 9.

The magnitude of our challenge

Human biology is complex, and research continues to reveal that the underlying mechanisms of cancer are even more diverse and elusive than previously understood—making early detection of cancer a challenge.

Extensive research suggests that cancer may be directly detectable with cell-free nucleic acids (DNA and RNA) shed by tumors into the bloodstream.

However, in order to develop effective early detection tests, we have to collect data from tens of thousands of people so that our machine learning algorithms can distinguish between people with and without cancer and this creates an unprecedented data challenge.

GRAIL’s approach

GRAIL aims to develop blood tests to detect cancer early, when treatment may be more successful.

To achieve this, we are building intelligent models to identify clinically actionable information from vast amounts of tumor genome data obtained through high-intensity sequencing.

We are supporting the development of our products with population-scale clinical studies to validate our hypotheses.

Learn More


To achieve this, we are building intelligent models to identify clinically actionable information from vast amounts of tumor genome data obtained through high-intensity sequencing.

We are supporting the development of our products with population-scale clinical studies to validate our hypotheses.

Learn More


Where hope meets rigor

At GRAIL, we’re unrelenting in the pursuit of our mission and will not stop until we find a better way. With the best talent in biology, clinical science, bioinformatics, deep learning, and engineering along with the passion of our leadership, our goal is to greatly decrease global cancer mortality.



Join our team


Stay in the know